title: Decomplementation with cobra venom factor prolongs survival of xenografted islets in a rat to mouse model.
abstract: Although the involvement of complement in hyperacute rejection of xenotransplants is well recognized, its role in rejection of devascularized xenografts, such as pancreatic islets, is not completely understood. In this study, we investigated whether complement participates in the immunopathology of xeno-islet transplantation in a concordant rat to mouse model. Rat pancreatic islets were implanted under the kidney capsule of normal and cobra venom factor (CVF)-decomplementized diabetic C57BL/6 mice. Graft survival was monitored by blood glucose levels. Deposition of IgM and C3 on grafted islets in vivo or on isolated islets in vitro (after incubation with normal and decomplementized mouse serum), as well as CD4- and CD8-positive leucocyte infiltration of grafts, was checked by immunohistochemistry. In addition, complement-mediated cytotoxicity on rat islet cells was evaluated by a 3-(4, 5-dimethythiazolyl)-2.5-diphenyl-2H-tetrazolium-bromide (MTT) assay. A significant C3 deposition was found on grafted islets from the first day after transplantation in vivo, as well as on isolated islets after incubation with mouse serum in vitro. By MTT assay, complement-mediated cytotoxicity for islet cells was found. Decomplementation by CVF decreased C3 deposition on either isolated or grafted islets, delayed CD4- and CD8-positive leucocyte infiltration, led to significant inhibition of complement-mediated cytotoxicity for islet cells, and prolonged graft survival (mean survival time 21.3 versus 8.5 days; P<0.01). Our results indicate that decomplementation can prolong the survival time of devascularized xenografts across concordant species. The deposition of complement on transplanted islets may contribute to xenograft rejection by direct cytotoxicity and by promoting leucocyte infiltration.
authors.affiliation: Division of Surgical Research, Department of Surgery, University Hospital of Geneva, Geneva, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Oberholzer
authors.forename: D
authors.initials: D
authors.lastname: Yu
authors.forename: F
authors.initials: F
authors.lastname: Triponez
authors.forename: N
authors.initials: N
authors.lastname: Cretin
authors.forename: E
authors.initials: E
authors.lastname: Andereggen
authors.forename: G
authors.initials: G
authors.lastname: Mentha
authors.forename: D
authors.initials: D
authors.lastname: White
authors.forename: L
authors.initials: L
authors.lastname: Buehler
authors.forename: P
authors.initials: P
authors.lastname: Morel
authors.forename: J
authors.initials: J
authors.lastname: Lou
mesh_terms: D000818:Animals; D003176:Complement C3 / Q000378:metabolism; D003169:Complement Inactivator Proteins / Q000494:pharmacology*; D003165:Complement System Proteins / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D004546:Elapid Venoms / Q000494:pharmacology*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D007075:Immunoglobulin M / Q000378:metabolism; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D003176:Complement C3; D003169:Complement Inactivator Proteins; D004546:Elapid Venoms; D007075:Immunoglobulin M; C016310:cobra venom factor; D003165:Complement System Proteins